We previously showed that nitric oxide (NO) induces overexpression of cyclooxygenase-2 (COX-2) and production of prostaglandin E 2 in cancer cells. Here, we investigated the mechanisms by which NO induces COX-2 expression in cancer cells. We found that the cAMP-response element (CRE) is a critical factor in NOinduced COX-2 expression in all cells tested. We found that in cancer cells, three transcription factors (TFs) -cAMP response element-binding protein (CREB), activating transcription factor-2 (ATF-2) and c-jun, bound the CRE in the COX-2 promoter, and their activities were increased by addition of the NO donor, S-nitroso-Nacetyl-D,L-penicillamine (SNAP). NO-induced activation of soluble guanylate cyclase (sGC), p38 and c-Jun NH 2 -terminal kinase (JNK) upregulated the three TFs, leading to COX-2 overexpression. Addition of dibutyryl-cGMP (db-cGMP) induced COX-2 expression in a manner similar to SNAP; this induction was blocked by a p38 inhibitor (SB202190), but not by a JNK inhibitor (SP600125). NO-induced cGMP was found to activate CREB and ATF-2 in a p38, but not c-jun-dependent manner, while NO induced JNK in a cGMP-independent manner, leading to subsequent activation of c-jun and ATF-2. These results suggest that the low concentrations of endogenous NO present in cancer cell may induce the expression of many genes, including COX-2, which promotes the growth and survival of tumor cells.
Introduction
In recent years, nitric oxide (NO) has been recognized as a fundamental signaling molecule for the maintenance of homeostasis, a potent cytotoxic effector molecule involved in the pathogenesis of a wide range of human diseases (Liaudet et al., 2000) . NO is also an important mediator of inflammatory responses, prompting researchers to investigate whether NO interacts with another inflammatory factor, cyclooxygenase-2 (COX-2), in inflammatory cells. Previous reports showed that when inducible NO synthase (iNOS) was upregulated in inflammatory cells, COX-2 expression increased in a similar pattern (Surh et al., 2001) . NO has been reported to activate or inhibit COX-2 activity, depending on the concentration of NO, the timing of its induction, and the investigated cell type (Salvemini et al., 1993; Stadler et al., 1993; Tsai et al., 1994; Habib et al., 1997) .
It is well known that iNOS and COX-2 are simultaneously upregulated in various cancers, including head and neck cancer (Gallo et al., 1998; Chan et al., 1999; Son et al., 2001; Lee et al., 2002; Nose et al., 2002) . However, the direct cross-talk between NO and COX-2 in cancer cells has not been fully elucidated. Recently, we showed that NO induces COX-2 expression and prostaglandin E 2 (PGE 2 ) production in head and neck cancer cells, and that this effect is blocked by iNOS inhibitors. Similar results have been shown in other cancer cells, including hepatocarcinoma, gastric cancer and cervical cancer (Park et al., 2003) .
The role of NO in cancer is unclear and somewhat controversial, but may be divided into two broad functions: promotion of cancer progression and/or cytotoxicity to cancer cells. At high concentrations, NO acts as a tumoricidal factor, though it can also initiate tumorigenesis through genotoxic mutations. At lower (noncytotoxic) levels, NO has been reported to promote cancer progression during invasion, metastasis and angiogenesis (Gallo et al., 1998; Wink et al., 1998; Surh et al., 2001) . In cancer cells, COX-2 is known to facilitate malignant progression though various mechanisms (Sheng et al., 2001; Pai et al., 2002; Sun et al., 2002; Tanabe and Tohnai, 2002) . COX-2 is one of the immediate early response genes; its expression is regulated by trans-activation of a regulatory signal leading to activation of specific transcription factors (TFs) that subsequently bind regulatory sites in the COX-2 promoter. NF-kB, NF-IL6, PEA-3 and cAMP response element-binding protein (CREB)/ activator protein-1 (AP-1) have been suggested to play important roles in the regulation of the COX-2 expression in various cells; their response elements have been located close to the transcription initiation site of the COX-2 promoter (Howe et al., 2001; Tang et al., 2001; Tamura et al., 2002; Tanabe and Tohnai, 2002) . NO affects the activity of many TFs in various pathways. NO transduces intracellular signaling through the activation of sGC, which is the only receptor conclusively proven to mediate interactions between NO and its signaling molecules (Bogdan, 2001) . However, it is not yet known how COX-2 expression is upregulated by endogenous NO in cancer cells, or whether NO plays an important role in carcinogenesis.
Here, we investigated the mechanisms of NO-induced overexpression of COX-2 by analysing the action of NO on signals related to the regulation of COX-2 expression in cancer cells. We found that NO increases COX-2 expression through the cAMP response element (CRE) of the COX-2 promoter in cancer cells. The data suggest that the low concentrations of endogenous NO present in cancer cells may induce the expressions of diverse genes, such as COX-2, which promotes the growth and survival of tumor cells.
Results

CRE is an important transcription regulatory element for basal and NO-induced COX-2 expression in SNU-1041 cells
We performed luciferase assays with plasmids containing partial COX-2 promoter sequences Figure 1b ) and observed that the CRE was a critical regulatory motif for basal and NO-induced overexpression of COX-2 in SNU-1041 cells. Basal luciferase activities were significantly lower in cells transfected with plasmids containing mutant CRE (CRM, CRM þ KBM, CRM þ ILM and Triple M) versus those with other plasmids (À327/ þ 59(S), KBM, ILM and KBM þ ILM) (Figure 1a) . Similarly, cells transfected with plasmids harboring mutant CRE sequences showed significantly lower inductions of luciferase activity in response to the NO donors, phorbol 13-myristate 12-acetate (PMA) or S-nitroso-N-acetyl-D, L-penicillamine (SNAP) (Figure 1b ). These data indicate that CRE is a critical regulatory motif for NO-induced COX-2 expression.
CREB, activating transcription factor-2 (ATF-2) and c-jun bind to the CRE of the COX-2 promoter in SNU-1041 cells
To identify TFs that interact with the CRE of the COX-2 promoter, we performed a gel shift assay using four representative members of the CREB/ATF-2/AP-1 family of TFs: CREB, ATF-2, c-jun and c-fos (Figure 2a ). Treated with antibody to CREB, ATF-2 and c-jun antibodies, but not by the anti-c-fos antibody, the decrease and dragged shift of the binding bands were detected in repeated experiments. Addition of unlabeled competitors against the CREB and AP-1 elements also decreased the intensity of the bands, while addition of an unlabeled competitor for NF-kB (cold control) did not. These results indicate that at least three of them and Triple M) and subsequently treated with 500 mM SNAP or 10 nM PMA for 18 h. Total cell lysates were prepared and COX-2 promoter activities were determined. Luciferase activity was normalized in relation to cotransfection with 0.5 mg pSV-b galactosidase control vector, and is presented in relative luciferase units (RLUs). Vertical bars indicate the standard deviation (s.d.) (CREB, ATF-2 and c-jun) control COX-2 expression by binding to the CRE of the COX-2 promoter.
NO phosphorylates and activates CREB, ATF-2 and c-jun in SNU-1041 cells
We next used the PathDetect Trans-Reporting system (Stratagene, La Jolla) to examine whether NO is capable of activating CREB, ATF-2 and/or c-jun. We found that NO treatment increased the activities of these TFs by 2-to 2.5-fold (Figures 4c and 5a ). Western blotting revealed that CREB and c-jun were phosphorylated in cells treated with NO for 4-12 h (Figure 2b ). These data indicate that NO activates the tested TFs via phosphorylation, providing a convincing link between NO and increased COX-2 expression.
NO-induced COX-2 expression is mediated partially through the cGMP-dependent pathway As NO has been reported to control cellular signaling and gene expression through both cGMP-dependent (via activation of sGC) and -independent means (Bogdan, 2001) , we examined whether cGMP is an upstream regulator of NO-induced COX-2 expression. SNU-1041 cells were treated with dibutyryl-cGMP (db-cGMP) for 18 h and their COX-2 expression was examined. The COX-2 expression in cells treated with db-cGMP was comparable to that in SNAP-treated cells (Figure 3a) , and SNAP-induced COX-2 expression was inhibited by the NO-sensitive sGC inhibitor, 1H-[1,2,4]oxadiazolo[4,3,-a]quinoxalin-1-one (ODQ) (Figure 3b ). These observations suggest that NO activates sGC to induce cGMP, leading to signals aimed at regulating COX-2 expression. P-labeled oligonucleotides containing the CRE site of COX-2, and 2 ml antibody and 1 ml unlabeled oligonucleotide competitors (25 Â ) were added for competition assays. The unlabeled competitor for NF-kB was used as a cold control. (b) For Western blotting, cells were treated with 500 mM SNAP for 3 or 6 h. Total cellular proteins were extracted, 40 mg was loaded per lane, and the resulting immunoblots were probed for with antibodies against phospho-CREB, phospho-c-jun, CREB and c-jun
Figure 3 NO-induced COX-2 expression is mediated, in part, via the cGMP-dependent pathway in SNU-1041 cells. (a) Cells were treated with 1 or 2 mM dibutyryl-cGMP (db-cGMP) for 18 h and total cellular proteins (40 mg) were separated and transferred for Western blotting with an anti-COX-2 antibody. (b) Cells harboring the COX-2 promoter (À1432/ þ 59) containing plasmid were incubated with 50 mM ODQ, 500 mM SNAP or 500 mM SNAP þ 50 mM ODQ for 18 h and COX-2 expression was analysed in terms of luciferase activity normalized against that of b-galactosidase. The results presented are representative of three independent experiments, with the vertical bars representing the s.d.
NO induces COX-2 expression via activation of p38 and c-Jun NH 2 -terminal kinase (JNK)
As three MAP kinases were known to be upstream regulators of COX-2 expression, we examined whether extracellular signal-regulated kinase (ERK), p38 and JNK were related to NO-induced COX-2 expression. NO-induced COX-2 expression was blocked by the p38 inhibitor, SB202190, and the JNK inhibitor, SP600125 (Figure 4a ), but not by the ERK inhibitors, U0126 and PD153015 (data not shown). In addition, Western blotting revealed that the phosphorylation levels of p38 and JNK increased after 2-8 h of treatment with SNAP ( Figure 4b ), indicating that NO increased the phosphorylation of p38 and JNK. Furthermore, SB202190 treatment inhibited the NO-induced activation of CREB and ATF-2, while SP600125 treatment inhibited the NO-induced activation of ATF-2 and c-jun. These data indicate that among the CREassociated TFs in the COX-2 promoter, CREB is activated by p38, c-jun is activated by JNK, and ATF-2 is activated by both ( Figure 4c ).
NO-induced activation of p38 is cGMP-dependent, while that of JNK is cGMP-independent
As we found that cGMP and two MAP kinases mediated NO-induced COX-2 expression, we examined whether there was any interaction between cGMP and MAP kinases in NO-induced COX-2 expression. Treatment of cells with db-cGMP upregulated the activity of
Figure 4 NO induces COX-2 expression via activation of p38 and JNK. (a) Cells were treated with 12.5 mM SB202190 (p38 MAPK inhibitor) or 10 mM SP600125 (JNK inhibitor) in the presence or absence of 500 mM SNAP for 18 h. Total proteins were extracted and 40 mg per lane was resolved, blotted and subjected to Western blotting with antibodies against COX-2. (b) Cells were treated with 500 mM SNAP for 2 or 4 h, and 40 mg of total protein was resolved and immunoblotted with antibodies against phospho-JNK, JNK, phospho-p38 and p38. (c) Cells transfected with 0.05 mg of pFA-ATF-2, pFA2-CREB, or pFA2-cJun were treated with 500 mM SNAP, 500 mM SNAP þ 12.5 mM SB202190 or 500 mM SNAP þ 10 mM SP600125 for 18 h, cell lysates were prepared, and RLUs was measured. Luciferase activity was normalized in relation to that of b-galactosidase. The vertical bars represent the s.d.
Figure 5 NO activation of p38 is cGMP-dependent, while that of JNK is cGMP-independent. Cells transfected with the indicated plasmids were treated for 18 h with (a) 2 mM db-cGMP or 500 mM SNAP, or (b) 2mM db-cGMP, 2 mM db-cGMP þ 12.5 mM SB202190, or 2 mM db-cGMP þ 10 mM SP600125. (c) Cells transfected with pFA2-CREB were treated for 18 h with 2 mM db-cGMP, 2 mM db-cGMP þ 200 mM 2-3-dda, 2 mM dbcGMP þ 200 mM Rp-8-pCPT-cGMPs, 2 mM db-cGMP þ 2 mM Bisindolylmaleimide I or 2 mM db-cGMP þ 1 mM Ro-31-8220. Total cell lysates were extracted and RLUs were measured. Luciferase activities were normalized to that of b-galactosidase the p38 targets -CREB and ATF-2 -but not that of the JNK target -c-jun (Figure 5a ). The db-cGMP-induced activities of CREB and the COX-2 promoter were blocked by the p38 inhibitor but not by the JNK inhibitor ( Figure 5b ). These data suggest that NOinduced cGMP upregulates p38 MAP kinase but not JNK. In an effort to identify the cGMP-activated upstream regulators of p38, we tested the effect of PKA, protein kinase-C (PKC), and protein kinase G (PKG) on cGMP-induced p38 activation. The PKC inhibitors (Bisindolylmaleimide I and Ro-31-8220) reduced the activation of p38 by B30%, while inhibitors of PKA, PKG and Ca 2 þ had no detectable effects on the activation of p38 (Figure 5c ). Thus, while we were unable to specifically define the regulators upstream of cGMP in this pathway, our results suggest some possible involvement of PKC.
The effect of NOS inhibitors on the activities of CREB and c-jun in SNU-1041 cells
To examine the effect of endogenous NO on the intracellular signaling pathways in cancer cells, we treated SNU-1041 cells with the universal NOS inhibitor, N-nitro-L-arginine-methyl ester (L-NAME), and the iNOS-specific inhibitors, 1400W and Aminoguanidine (AG), and examined their effects on the activities of CREB and c-jun. Treatment of cells with the NOS inhibitors inhibited the activities of CREB and c-jun ( Figure 6 ). As NO-induced activation of these TFs is critical to the upregulation of COX-2 expression, these results suggest that COX-2 expression is likely to be decreased by blockage of NO production.
The effect of NO on COX-2 expression in other cancer cells
We previously observed that NO induces COX-2 overexpression in various cancer cells (Park et al., 2003) . To investigate whether the NO-induced responses identified in this study are seen in cancer cells other than SNU-1041, we tested the effect of NO on another head and neck cancer cell line (PCI-13) and two cell lines originating from other cancer types (SNU-668 and HeLa). In PCI-13 and HeLa cells, the CRE was important for NO-induced COX-2 expression (Figure 7a ), and this increase in COX-2 expression was blocked by the p38 inhibitor (Figure 7b and c) . Furthermore, NO treatment upregulated the p38 targets, CREB and ATF-2, in these cells (Figure 7d, e) . In SNU-668, COX-2 expression was increased by NO treatment, and this effect was partially reduced by p38 and JNK inhibitors (Figure 7c) . Collectively, these observations indicate that NO upregulates COX-2 expression by activating p38 and/or JNK in diverse cancer cells.
Discussion
We previously reported that NO induces COX-2 expression in cancer cells (Park et al., 2003) . Other groups have noted that while iNOS and COX-2 are barely detectable in resting inflammatory cells, their expression levels are transiently upregulated in response to signals such as growth factors and stress (Posadas et al., 2000; Surh et al., 2001) . However, we have observed that iNOS and COX-2 are constitutively overexpressed in all tested head and neck squamous cell carcinoma (HNSCC) cell lines, prompting us to question whether the regulatory mechanisms of their expression differ in inflammatory and cancer cells.
It has been well established that NF-kB, NF-IL6, PEA-3 and CREB/AP-1 are the main TFs responsible for the regulation of COX-2 expression (Howe et al., 2001; Tang et al., 2001; Tamura et al., 2002; Tanabe and Tohnai, 2002) . In addition, a growing body of evidence indicates that NF-kB plays a central role in the general inflammatory response and may be important in the upregulation of COX-2 expression in macrophage-like cells (Chabot-Fletcher, 1996) . NF-kB has been suggested to play a role in the regulation of COX-2 expression in cancer cells (Luque and Gelinas, 1997; Surh et al., 2001 ), but CRE-binding factors have been more frequently associated with COX-2 expression in these cells (Xu et al., 1997; Guo et al., 2001; Subbaramaiah et al., 2002) . In this study, we observed that the CRE element is critical for activation of the COX-2 promoter in all cells tested. Furthermore, a mutation in the NF-kB binding site had no effect on COX-2 expression, and the NF-kB inhibitors tested in this work had no affect on expression of COX-2 (data not shown). These observations suggest that differential COX-2 expression in cancer cells may depend on epigenetic events within the regulatory region of genes or on intracellular signaling generated during carcinogenesis .
We investigated whether the NO-induced overexpression of COX-2 in cancer cells was mediated by CRE Figure 6 The effect of NOS inhibitors on the activity of CREB and c-jun in SNU-1041 cells. Cells transfected with the indicated plasmids were treated for 18 h with 1 mM L-NAME, 100 mM 1400W or 2 mM Aminoguanidine. Total cell lysates were extracted and the RLUs were measured. Luciferase activities were normalized to that of b-galactosidase Figure 7 The effect of NO on COX-2 expression in other cancer cells. (a) The COX-2 promoter activity was measured in PCI-13 and HeLa cells transfected with a partial COX-2 promoter (À327/ þ 59(S), KBM, CRM or ILM). (b) PCI-13 or HeLa cells transfected with the partial COX-2 promoter (À1432/ þ 59) were treated for 18 h with 500 mM SNAP, 500 mM SNAP þ 12.5 mM SB202190 or 500 mM SNAP þ 10 mM SP6001125. Cell extracts were screened for COX-2 promoter activity. (c) Un-transfected PCI-13, HeLa and SNU-668 cells were treated for 18 h with 500 mM SNAP, 500 mM SNAP þ 12.5 mM SB202190 or 500 mM SNAP þ 10 mM SP6001125. Cell extracts (40 mg of total protein) were used for Western blotting. The variation of COX-2 expression by p38 and JNK inhibitors was analysed quantitatively by densitometry and indicated in figure. (d, e) SNAP (500 mM) was added for 18 h to (d) PCI-13 and (e) HeLa cells transfected with pFA-ATF-2, pFA2-CREB or pFA2-cJun. Cell lysates were used to determine the activity of each transcription factor element-interacting factors. AP-1 family members bind to the CREB site in many cells (Park et al., 1999) . Although the CRE sequence in the COX-2 promoter (5 0 -TTCGTCA-3 0 ) differs slightly from the consensus sequences for CREB (5 0 -TGACGTCA-3 0 ) and AP-1 (5 0 -TGAGTCA-3 0 ), studies have shown that CREB/ATF-2 and AP-1 interact with the CRE of COX-2 (Xu et al., 1997; Guo et al., 2001) . Similarly, we observed that CREB, ATF-2 and c-jun, but not c-fos, bind to the CRE of the COX-2 promoter in the tested cells. In addition, we showed that NO activates CREB, ATF-2 and c-jun. However, the NO-induced activations of these factors appear to be regulated by different mechanisms. Phosphorylation of CREB was increased by the NOinduced activation of sGC, which subsequently activated p38 mitogen-activated protein kinase (MAPK), an upstream regulator of CREB. In contrast, c-jun was phosphorylated by the direct activation of JNK by NO, and ATF-2 activity was upregulated by both p38 and JNK (Figure 8 ). We were unable to identify the specific molecule linking cGMP signaling to activation of p38, but did observe that inhibition of PKC reduced p38 activation by B30%. Previous studies reported that p38 could be activated by PKG via an unknown mechanism (Browning et al., 2000) . However, PKA, PKG and Ca 2 þ did not appear to be involved in NO-induced upregulation of p38, suggesting that one or more other regulator(s) may participate in the activation of p38 by cGMP in our model.
Our results indicate that NO appears to upregulate various signaling molecules, leading to activation of TFs related to CRE of COX-2 promoter and increased expression of COX-2 in cancer cell lines derived from HNSCC (SNU-1041, PCI-13), cervical cancer (HeLa), and gastric cancer (SNU-668) tissues. In addition, another group has shown that the effect of NO on PEA-3-mediated induction of COX-2 is relevant in colorectal cancer cells (Liu et al., 2004) . This means that NO might affect COX-2 expression in various mechanisms.
Other potential upstream regulators of COX-2 overexpression in cancer cells reportedly include epidermal growth factor (EGF) receptor activation (Coffery et al., 1997) , Her-2/neu activation (Vadlamudi et al., 1999) , p53 mutation (Han et al., 2002) and ras mutation (Slice et al., 2000) . Interestingly, Her-2/neu activation and ras mutation both lead activation of the CRE element in the COX-2 promoter (Slice et al., 2000; Subbaramaiah et al., 2002) .
Unlike lipopolysaccharide (LPS), EGF and PMA, which strongly induce COX-2, NO is a relatively weak inducer of COX-2 expression. While these strong inducers are capable of triggering increased COX-2 expression even in cells with low basal COX-2 expression, our data indicate that NO was only able to efficiently induce COX-2 expression in cells with moderate to strong basal COX-2 expression. We thus postulate that in cancer cells, the COX-2-inducible signaling molecules are constitutively activated such that they are sensitive to further activation by NO. In noncancerous cells, however, the NO-responsive molecules are only weakly activated and are unable to respond to NO. Thus, NO may act to accelerate existing intracellular signals rather than generating new signals.
COX-2 is thought to play an important role in carcinogenesis, suggesting that its blockade could be beneficial in terms of cancer management. However, regulation of COX-2 expression is a complex process mediated by numerous factors, complicating efforts to clinically block COX-2 expression. Moreover, the currently available COX-2 inhibitors block both COX-1 and COX-2 in normal cells during inflammatory responses, limiting their applicability to cancer therapy. Thus, it is important to identify differences in regulation of COX-2 expression between cancerous and noncancerous cells, as these differences could allow targeting of the cancer-specific COX-2 pathway(s) for novel therapeutic strategies.
In conclusion, our data suggest that the cAMPresponse element is a key regulator of COX-2 expression in cancer cells (i.e. head and neck cancer cells), and that endogenous or abnormally induced NO in the cancer microenvironment may upregulate COX-2 expression through the activation of TFs capable of binding the Figure 8 Possible mechanisms of NO-derived signal contributions to COX-2 expression in cancer cells. Endogenous or abnormally induced NO in the cancer microenvironment may upregulate COX-2 expression via activation of the transcription factors that associate with the CRE of the COX-2 promoter. Our data seem to suggest that NO may accelerate existing intracellular signals, rather than generating new signaling. We thus postulate that in cancer cells, NO is able to upregulate the expression of COX-2 because COX-2-inducible signaling molecules are already constitutively activated, leaving them sensitized to NO signaling. In noncancer cells, however, the NO-responsive molecules are only weakly activated, so NO is unable to induce COX-2 expression. In this way, NO may induce the expression of COX-2 and possibly other factors that promote the growth and survival of tumor cells CRE in the COX-2 promoter. NO appears to accelerate existing intracellular signals rather than generating new signaling, and thus may promote the growth and survival of tumor cells. These novel results suggest that additional studies on the role of NO in carcinogenesis may be warranted and that iNOS should potentially be re-evaluated as a molecular target for cancer prevention and treatment.
Materials and methods
Cell culture
HNSCC cells line SNU-1041 was obtained from the Korean Cell Line Bank (Seoul National University, Seoul, Korea) (Chung et al., 2000) , while HNSCC cell line PCI-13 was obtained from the Pittsburgh Cancer Institute (University of Pittsburgh, PA, USA) (Heo et al., 1989) . We additionally used gastric cancer cell line SNU-668 and HeLa. All cells were cultured in DMEM or RPMI-1640 media supplemented with 10 mg/ml gentamicin and 10% fetal bovine serum (FBS). Cells were maintained at 371C in a humidified, 5% CO 2 , 95% air atmosphere and routinely subcultured using trypsin-EDTA (0.25% w/v). All cell culture reagents were obtained from Gibco BRL (Grand Island, NY, USA), unless otherwise stated.
Chemicals SNAP (NO donor), db-cGMP, PMA, L-NAME (universal NOS inhibitor), AG (specific iNOS inhibitor), LPS and EGF were obtained from Sigma Chemical Co. (St Louis, MO, USA). ODQ (soluble guanylate cyclase (sGC) inhibitor), SB202190 (p38 MAPK inhibitor), SP600125 (JNK inhibitor), U0126 (ERK inhibitor), PD153015 (ERK inhibitor), 2 0 ,3 0 -Dideoxyadenosine (2-3-DDA, PKA inhibitor), 2-[1-93-Dimethylaminopropyl]-1H-indol-3-yl)-3-(1H-indol-3-yl)-maleimide (Bisindolylmaleimide I, PKC inhibitor), Bisindolylmaleimide IX (Ro-31-8220, PKC inhibitor) and Rp-8-pCPTcGMPs (PKG inhibitor) were obtained from Calbiochem (La Jolla, CA, USA). 1400W (specific iNOS inhibitor) was obtained from Cayman (Ann Arbor, MI, USA). Most chemicals were utilized according to the provided suggestion (IC50 and references), with the exception of SNAP and 1400W, which were applied according to our previous optimization study results (Park et al., 2003) .
COX-2 promoter activity assay
The COX-2 promoter constructs (À1432/ þ 59(L), À327/ þ 59 (S), KBM, ILM, CRM, KBM þ ILM, KBM þ CRM, ILM þ CRM, and Triple M) were generated as previously described (Inoue et al., 2000) . The PGL2-Basic control vector was purchased from Promega (Madison, WI, USA), and the pSV-b galactosidase control vector was a kind gift from Dr Yung-Jue Bang (Cancer Research Institute, Seoul National University, Seoul, Korea). Cells were seeded at 10 5 /well in 12-well culture plates and grown to 70-80% confluence in complete growth media containing 10% FBS. Cells were cotransfected with 0.5 mg COX-2 promoter construct and 0.5 mg pSV-b galactosidase control vector using Lipofectamine Plus according to the manufacturer's instructions (Life Technologies, Gaithersburg, MD, USA). After 4 h, medium containing 10% FBS was added and cells were incubated for an additional 20 h. Subsequently, cells were incubated in serum-free medium for 24 h and then treated for 18 h with the NO donor and/or other chemicals as indicated. Luciferase activity was measured using a TR717 Microplate Luminometer with a Bioluminescent Reporter Gene Assay kit, according to the manufacturer's instructions (Tropix, Bedford, MA, USA). The pGL2-Basic vector without insert was used as the negative control in transfection experiments. Luciferase activity was normalized according to that of b-galactosidase.
Gel shift assay
Gel shift experiments were performed using a gel shift assay system according to the manufacturer's instructions (Promega, Madison, WI, USA). Cells were harvested and nuclear extracts were prepared. We designed and synthesized double-stranded oligonucleotides containing the CRE site of the COX-2 promoter (5 0 -AAA CAG TCA TTT CGT CAC ATG GGC TTG-3 0 ). Oligonucleotides containing the consensus sequences of the CREB (5 0 -AGA GAT TGC CTG ACG TCA GAG AGC TAG-3 0 ), AP-1 (5 0 -CGC TTG ATG AGT CAG CCG GAA-3 0 ) and NF-kB (5 0 -AGT TGA GGG GAC TTT CCC AGG-3 0 ) sites were obtained from Promega (Madison, WI, USA) and used as unlabeled competitors. The complementary oligonucleotides containing the CRE of the COX-2 promoter were annealed in 20 mM Tris-Cl (pH 7.4), 50 mM NaCl, 10 mM MgCl 2 , and 1 mM dithiothreitol. Annealed oligonucleotides were phosphorylated at the 5 0 -end with [g-32 P]ATP and T4 polynucleotide kinase. The binding reaction was performed by incubating 5 mg of nuclear proteins with 5 Â binding buffer (50 mM Tris-Cl (pH 7.5), 20% glycerol, 5 mM MgCl 2 , 2.5 mM EDTA, 2.5 mM dithiothreitol, 250 mM NaCl and 0.25 mg/ml poly (dI-dC)) in a final volume 9 ml for 10 min at room temperature. Then, 1 ml of the labeled oligonucleotide was added to the reaction mixture and incubated for 20 min at room temperature. For the competition assay, unlabeled oligonucleotides containing the CRE of COX-2, or the CREB, AP-1 or NF-kB consensus sequences were used. The samples were incubated with anti-CREB, anti-ATF-2, anti-c-jun or anti-c-fos antibodies for 1 h, followed by addition of 32 Plabeled oligonucleotides containing the CRE site of COX-2. Samples were electrophoresed on a Novex 6% DNA retardation gel (Invitrogen). The gel image was transferred to an imaging plate (BAS-MP 2040S, Fuji Photo Film Co., Tokyo, Japan), and the degree of binding was calculated based on hybridization signals measured with a bio-imaging analyser (FRA2000 system, Fuji Photo Film Co., Tokyo, Japan).
TF activation assay
The fusion trans-activator plasmids (pFA-ATF-2, pFA2-CREB, and pFA2-cJun) consisting of the DNA binding domain of Gal4 (residue 1-147) and the trans-activation domains of ATF-2, CREB or c-jun were purchased from Stratagene (La Jolla, CA, USA). pFC2-dbd, which contains only the DNA binding domain of Gal4 (residue 1-147), was used as the negative control. We performed experiments according to the manufacturer's instructions.
Protein extraction and Western blot analysis
Cultured cells were rinsed with PBS, suspended in lysis buffer (0.5% NP40, 50 mM Tris-Cl, 150 mM NaCl, 1 mM dithiothreitol, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 0.1 mM aprotinin, and 1 mM pepstatin A), and incubated at 41C for 30 min. The cell lysates were then centrifuged at 13 000 r.p.m. for 20 min at 41C, and then appropriate amount of supernatant (determined by protein assay) was mixed with 4 Â sample loading buffer and denatured for 10 min at 701C. The denatured protein samples were fractionated on 4-12% NuPAGE gels (Invitrogen, Carlsbad, CA, USA), transferred onto nitrocellulose membranes (Schleicher & Schuell, Dachen, Germany) and incubated with Tris-buffered saline containing 0.1% Tween-20 and 5% nonfat dry milk. The membranes were then incubated with anti-COX-2, anti-p38, anti-phospho-p38, anti-JNK, anti-phospho-JNK, anti-c-fos (all from Santa Cruz Biotechnology, Santa Cruz, CA, USA), monoclonal anti-atubulin (Sigma Chemical Co., St Louis, MO, USA), anti-CREB, anti-phospho-CREB, anti-ATF-2, anti-phospho-ATF-2, anti-c-jun or anti-phospho-c-jun (all from Cell Signaling Technology, Beverly, MA, USA) for 2 h at room temperature or overnight at 41C. Membranes were then washed (4 Â 15 min) with 1 Â TBS-T and incubated with horseradish peroxidase-conjugated secondary antibody (Pierce, Rockford, IL, USA) for 1 h. Immunoreactive proteins were visualized by development with the lumi-light Western blotting substrate (Roche Diagnostics GmbH, Mannheim, Germany) and exposure to X-ray film.
Statistical analysis
The data are presented as the mean7standard deviation (s.d.) of triplicates, or as a representative of three separate experiments. Levels of significance were determined between treated and untreated groups by two-sided Student's t-test.
Abbreviations NO, nitric oxide; iNOS, inducible nitric oxide synthase; COX-2, cyclooxygenase-2; CRE, cAMP-response element; sGC, soluble guanylate cyclase; PGE 2 , prostaglandin E 2 ; HNSCC, head and neck squamous cell carcinoma; MAPK, mitogenactivated protein kinase; ERK, extracellular signal-regulated kinase; JNK, c-Jun NH 2 -terminal kinase; CREB, cAMP response element-binding protein; ATF-2, activating transcription factor-2; AP-1, activator protein-1; PKA, cAMP-dependent protein kinase; PKC, protein kinase-C; PKG, protein kinase G.
